Fernanda Santana da Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fernanda Santana da Silva has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jefferson Oliveira Silva
Universidade Estadual de Montes Claros
2 shared publications - João José Lopes dos Santos Neto
Universidade Federal da Bahia
2 shared publications - Matheus Felipe Ferreira Aguiar
Department of Gastroenterology, Hospital das Clínicas, University of São Paulo, School of Medicine, Sao Paulo Brazil
2 shared publications - Rogério Gonçalves da Rocha
Universidade Estadual de Montes Claros
2 shared publications - Victor Hugo Dantas Guimarães
Institute for Research on Behavior and Food, Sao Paulo, Brazil; State University of Montes Claros - UNIMONTES, Brazil
2 shared publications - Elder Andrade Oliveira Filho
Universidade Federal de Minas Gerais
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by Universidade Estadual de Maringa in Acta Scientiarum. Health Sciences
- Vol. 48, e68269
Clinical and laboratory evaluation of patients with visceral leishmaniasis undergoing different therapeutic regimens of liposomal amphotericin B
Visceral Leishmaniasis (VL) is an infectious disease caused by protozoa of the Leishmania genus and is transmitted to humans by the bite of infected female Lutzomyia sandflies. Several treatment protocols for VL are available, including the utilization of liposomal amphotericin B. Nevertheless, the optimal protocol with the minimal adverse effects remains uncertain. In this context, the present study aims to assess the clinical and laboratory outcomes of patients with VL undergoing two distinct therapeutic regimens of liposomal amphotericin B. A cross-sectional study was conducted to analyze data from the medical records of patients diagnosed with VL between 2015 and 2019 in an endemic area in the northern region of the State of Minas Gerais, Brazil. All patients in the study were predominantly under the age of 10 years, with 70.4% being male (19 cases). In terms of clinical conditions, fever was present in 92.3% of cases, while splenomegaly and hepatomegaly occurred in 100% of patients. No significant differences were observed between the treatment regimens of liposomal amphotericin B at 4 mg (kg day-1)-1 for 5 days and 3 mg (kg day-1)-1 for 7 days. The data suggest that patients who received liposomal amphotericin B for both 5 and 7 days exhibited no clinically or laboratory differences compared to those who utilized liposomal amphotericin B for a five-day duration.
- 1 December 2025
- Published by Universidade Estadual de Maringa in Acta Scientiarum. Health Sciences
- Vol. 48, e68269
Open AccessClinical and laboratory evaluation of patients with visceral leishmaniasis undergoing different therapeutic regimens of liposomal amphotericin B
Visceral Leishmaniasis (VL) is an infectious disease caused by protozoa of the Leishmania genus and is transmitted to humans by the bite of infected female Lutzomyia sandflies. Several treatment protocols for VL are available, including the utilization of liposomal amphotericin B. Nevertheless, the optimal protocol with the minimal adverse effects remains uncertain. In this context, the present study aims to assess the clinical and laboratory outcomes of patients with VL undergoing two distinct therapeutic regimens of liposomal amphotericin B. A cross-sectional study was conducted to analyze data from the medical records of patients diagnosed with VL between 2015 and 2019 in an endemic area in the northern region of the State of Minas Gerais, Brazil. All patients in the study were predominantly under the age of 10 years, with 70.4% being male (19 cases). In terms of clinical conditions, fever was present in 92.3% of cases, while splenomegaly and hepatomegaly occurred in 100% of patients. No significant differences were observed between the treatment regimens of liposomal amphotericin B at 4 mg (kg day-1)-1 for 5 days and 3 mg (kg day-1)-1 for 7 days. The data suggest that patients who received liposomal amphotericin B for both 5 and 7 days exhibited no clinically or laboratory differences compared to those who utilized liposomal amphotericin B for a five-day duration.
- Open Access
- 2 October 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (13)
American Tegumentary Leishmaniasis in Montes Claros: an epidemiological study
Introduction: American Tegumentary Leishmaniasis (ATL), or kala azar, is a serious chronic disease caused by Leishmania spp. It is an infectious and non-contagious disease that affects both humans and several species of wild and domestic animals, presenting the clinical forms of cutaneous, mucocutaneous and diffuse cutaneous. ATL is classified as a generalized zoonotic disease that has a global impact. It is caused by protozoa of the genus Leishmania and is considered a serious public health problem. Objective: To describe the epidemiological profile of cases found in Montes Claros-MG. Methodology: An epidemiological assessment was performed based on secondary data from SINAN/MS from January 2010 to December 2015. Results: From 2010 to 2015, 286 cases of ATL were registered, with the majority of cases occurring in children under 19 years of age (31.81%) and patients over 59 years (17.83%) had a lower percentage of disease involvement. The first choice drug used by patients was Glucantime (87.06%). The most affected gender was male (52.44%) and most patients had no comorbidities (76.96%). Conclusion: In Montes Claros, Minas Gerais, ATL presented high cases during the research period. In this sense, this study guides the development of new researches that address and monitor the spread of the disease by monitoring urban areas concomitantly with the capture of animals for the presence of the parasite, thus assisting in public health decision-making in controlling the disease.
- 2 October 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (13)
Open AccessAmerican Tegumentary Leishmaniasis in Montes Claros: an epidemiological study
Introduction: American Tegumentary Leishmaniasis (ATL), or kala azar, is a serious chronic disease caused by Leishmania spp. It is an infectious and non-contagious disease that affects both humans and several species of wild and domestic animals, presenting the clinical forms of cutaneous, mucocutaneous and diffuse cutaneous. ATL is classified as a generalized zoonotic disease that has a global impact. It is caused by protozoa of the genus Leishmania and is considered a serious public health problem. Objective: To describe the epidemiological profile of cases found in Montes Claros-MG. Methodology: An epidemiological assessment was performed based on secondary data from SINAN/MS from January 2010 to December 2015. Results: From 2010 to 2015, 286 cases of ATL were registered, with the majority of cases occurring in children under 19 years of age (31.81%) and patients over 59 years (17.83%) had a lower percentage of disease involvement. The first choice drug used by patients was Glucantime (87.06%). The most affected gender was male (52.44%) and most patients had no comorbidities (76.96%). Conclusion: In Montes Claros, Minas Gerais, ATL presented high cases during the research period. In this sense, this study guides the development of new researches that address and monitor the spread of the disease by monitoring urban areas concomitantly with the capture of animals for the presence of the parasite, thus assisting in public health decision-making in controlling the disease.
- Open Access
- 1 January 2021
- Published by Universidade Estadual de Maringa in Acta Scientiarum. Health Sciences
- Vol. 43, e55223
Epidemiological aspects of visceral leishmaniasis in the municipality of Montes Claros-MG
Visceral leishmaniasis (VL), also known as 'calazar', is a serious chronic disease caused by Leishmania species from Leishmania (Leishmania) donovani complex, which the disease is characterized by abdominal swelling (hepatosplenomegaly) and may evolve to death in extreme cases. In this sense, the aim of our study was to assess the epidemiological profile of the cases found in Montes Claros (Minas Gerais state). A retrospective or cross-sectional study was carried out using secondary data provided by Health Information System (SINAN/HM) of Brazil from January 2010 to February 2020. Our data has shown that VL is an endemic disease in Montes Claros region, with 413 VL cases reported, 62.00% (252) male, average age +/- standard deviation (years), and 93.46% (386) lived in Montes Claros city. The presence of comorbidities was observed in 13.70% (54) of the patients and in 7.26% (30). As for the evolution of the disease, 246 (59.56%) were cured, 30 (7.26%) died due to VL. Between 2010 and 2015, Glucantime (R) stands out, in which 46 (11.13%) patients used the drug, followed by common Amphotericin B 24 (13.48%) and liposomal Amphotericin B 38 (21.34%). In the period between 2016 and 2020, the most prevalent drug was liposomal Amphotericin B, with 71 (29.83%) patients using it, followed by Glucantime (R) 45 (18.9%). The condition evolved to death. We conclude that Montes Claros is still an endemic area for VL with an increased number of cases over time and a noticeable shift in patient profile towards children and young people. Joint efforts from different areas of scientific knowledge and public health services are needed to improve the effectiveness of visceral leishmaniasis surveillance and control actions. The population can contribute to this process of disease prevention and control, through educational actions in health and the environment.
- 1 January 2021
- Published by Universidade Estadual de Maringa in Acta Scientiarum. Health Sciences
- Vol. 43, e55223
Open AccessEpidemiological aspects of visceral leishmaniasis in the municipality of Montes Claros-MG
Visceral leishmaniasis (VL), also known as 'calazar', is a serious chronic disease caused by Leishmania species from Leishmania (Leishmania) donovani complex, which the disease is characterized by abdominal swelling (hepatosplenomegaly) and may evolve to death in extreme cases. In this sense, the aim of our study was to assess the epidemiological profile of the cases found in Montes Claros (Minas Gerais state). A retrospective or cross-sectional study was carried out using secondary data provided by Health Information System (SINAN/HM) of Brazil from January 2010 to February 2020. Our data has shown that VL is an endemic disease in Montes Claros region, with 413 VL cases reported, 62.00% (252) male, average age +/- standard deviation (years), and 93.46% (386) lived in Montes Claros city. The presence of comorbidities was observed in 13.70% (54) of the patients and in 7.26% (30). As for the evolution of the disease, 246 (59.56%) were cured, 30 (7.26%) died due to VL. Between 2010 and 2015, Glucantime (R) stands out, in which 46 (11.13%) patients used the drug, followed by common Amphotericin B 24 (13.48%) and liposomal Amphotericin B 38 (21.34%). In the period between 2016 and 2020, the most prevalent drug was liposomal Amphotericin B, with 71 (29.83%) patients using it, followed by Glucantime (R) 45 (18.9%). The condition evolved to death. We conclude that Montes Claros is still an endemic area for VL with an increased number of cases over time and a noticeable shift in patient profile towards children and young people. Joint efforts from different areas of scientific knowledge and public health services are needed to improve the effectiveness of visceral leishmaniasis surveillance and control actions. The population can contribute to this process of disease prevention and control, through educational actions in health and the environment.